menu
    • menu
    [{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Ksana Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Ksana Health","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Ksana Health"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Janus Henderson Investors | Foresite Capital | Deep Track Capital | HBM Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Mebufotenin benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"ATAI Life Sciences \/ Janus Henderson Investors | Foresite Capital | Deep Track Capital | HBM Partners","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Janus Henderson Investors | Foresite Capital | Deep Track Capital | HBM Partners"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Janus Henderson Investors | Foresite Capital | Deep Track Capital | HBM Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Mebufotenin benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"ATAI Life Sciences \/ Janus Henderson Investors | Foresite Capital | Deep Track Capital | HBM Partners","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Janus Henderson Investors | Foresite Capital | Deep Track Capital | HBM Partners"}]

    Find Clinical Drug Pipeline Developments & Deals for Mebufotenin benzoate

    Menu

    Mebufotenin benzoate

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ATAI Life Sciences

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ATAI Life Sciences

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Janus Henderson Investors | Foresite Capital | Deep Track Capital | HBM Partners

                            Deal Size : $149.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Atai Life Sciences Closes Public Offering, Fully Exercises Option for Additional Shares

                            Details : The proceeds from the offering will be used to fund the clinical development of Mebufotenin Benzoate, a controlled substance targeting the 5-HT2A receptor for mental health disorders.

                            Product Name : BPL-003

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            October 20, 2025

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Janus Henderson Investors | Foresite Capital | Deep Track Capital | HBM Partners

                            Deal Size : $149.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ATAI Life Sciences

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ATAI Life Sciences

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Janus Henderson Investors | Foresite Capital | Deep Track Capital | HBM Partners

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Atai Life Sciences Plans Public Offering of Common Shares

                            Details : The proceeds from the offering will be used to fund the clinical development of Mebufotenin Benzoate, a controlled substance targeting the 5-HT2A receptor for mental health disorders.

                            Product Name : BPL-003

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            October 16, 2025

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Janus Henderson Investors | Foresite Capital | Deep Track Capital | HBM Partners

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ATAI Life Sciences

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ATAI Life Sciences

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            atai Completes Enrollment for BPL-003 Phase 2b in Treatment-Resistant Depression

                            Details : BPL-003 (mebufotenin) is a novel, synthetic, patent-protected benzoate salt formulation of mebufotenin. It is being evaluated for the treatment of treatment-resistant depression.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            March 05, 2025

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ATAI Life Sciences

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ATAI Life Sciences

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Atai Touts Positive Data for Psychedelic Therapy in Alcohol Use Disorder

                            Details : BPL-003 (mebufotenin) is a novel, synthetic, patent-protected benzoate salt formulation of mebufotenin. It is being evaluated for the treatment of treatment of alcohol use disorder.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            January 28, 2025

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ATAI Life Sciences

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ATAI Life Sciences

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            atai Doses First Patient in Part 2 of Beckley's Phase 2a of BPL-003 Adjunctive to SSRIs

                            Details : BPL-003 is a novel, synthetic, patent-protected benzoate salt formulation of 5-MeO-DMT (mebufotenin) administered intranasally. It is being evaluated for treatment resistant depression.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            April 24, 2024

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Beckley Psytech

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Beckley Psytech

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Beckley Psytech Reports Positive Data from Phase IIa Study Of BPL-003

                            Details : BPL-003 (mebufotenin) is Beckley Psytech’s novel synthetic formulation of 5-MeO-DMT administered intranasally, being evaluated for treatment-resistant depression.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            March 27, 2024

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Beckley Psytech

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Beckley Psytech

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : ATAI Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            atai Life Sciences Invests in Beckley Psytech for Psychedelic Development

                            Details : Funds will advance BPL-003 (mebufotenin) and ELE-101 (psilocin) as part of atai’s mental health platform, focusing on short-duration psychedelic candidates.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            January 04, 2024

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : ATAI Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Beckley Psytech

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Beckley Psytech

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Patient Dosed in Beckley Psytech’s International Phase IIb Study of BPL-003, a Novel Synthetic Intrana...

                            Details : BPL-003, a novel synthetic formulation of 5-MeO-DMT (also known as mebufotenin), which is investigated for the treatment of treatment Resistant Depression (TRD).

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            October 24, 2023

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Beckley Psytech

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Beckley Psytech

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Patient Dosed in Beckley Psytech’s Phase IIa Study of BPL-003 for Treatment Resistant Depression

                            Details : BPL-003 (mebufotenin) is a psychoactive indolealkylamine derivative of tryptamine and binds to a variety of serotonergic 5-HT receptors which is considered to be the mechanism for its psychoactive effects.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            May 04, 2023

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Beckley Psytech

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Beckley Psytech

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Beckley Psytech Initiates Phase IIa Study of 5-MeO-DMT Candidate BPL-003 for Alcohol Use Disorder

                            Details : BPL-003 (mebufotenin) is a psychoactive indolealkylamine derivative of tryptamine and binds to a variety of serotonergic 5-HT receptors which is considered to be the mechanism for its psychoactive effects.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            April 05, 2023

                            Lead Product(s) : Mebufotenin benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth